Evelo Biosciences, Inc. (NASDAQ:EVLO) Expected to Announce Earnings of -$0.58 Per Share

Analysts expect Evelo Biosciences, Inc. (NASDAQ:EVLOGet Rating) to post ($0.58) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Evelo Biosciences’ earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.56). Evelo Biosciences posted earnings per share of ($0.59) during the same quarter last year, which suggests a positive year over year growth rate of 1.7%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Evelo Biosciences will report full-year earnings of ($2.07) per share for the current fiscal year, with EPS estimates ranging from ($2.31) to ($1.29). For the next fiscal year, analysts forecast that the company will report earnings of ($2.14) per share, with EPS estimates ranging from ($2.63) to ($1.60). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Evelo Biosciences.

Evelo Biosciences (NASDAQ:EVLOGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.05.

Separately, Zacks Investment Research cut Evelo Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 30th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $20.38.

Evelo Biosciences stock traded up $0.26 during trading hours on Friday, hitting $2.12. The stock had a trading volume of 164,219 shares, compared to its average volume of 310,410. The company has a 50-day moving average of $2.66 and a two-hundred day moving average of $4.83. The company has a quick ratio of 2.67, a current ratio of 2.67 and a debt-to-equity ratio of 5.37. The company has a market cap of $113.76 million, a PE ratio of -0.91 and a beta of 1.75. Evelo Biosciences has a fifty-two week low of $1.42 and a fifty-two week high of $17.13.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Evelo Biosciences in the 3rd quarter valued at $74,000. New York State Common Retirement Fund lifted its stake in shares of Evelo Biosciences by 57.8% in the 4th quarter. New York State Common Retirement Fund now owns 15,765 shares of the company’s stock valued at $96,000 after purchasing an additional 5,777 shares during the period. Credit Suisse AG lifted its stake in shares of Evelo Biosciences by 7.0% in the 3rd quarter. Credit Suisse AG now owns 3,310,911 shares of the company’s stock valued at $23,309,000 after purchasing an additional 215,192 shares during the period. Citigroup Inc. lifted its stake in shares of Evelo Biosciences by 297.6% in the 3rd quarter. Citigroup Inc. now owns 5,742 shares of the company’s stock valued at $40,000 after purchasing an additional 4,298 shares during the period. Finally, ProShare Advisors LLC acquired a new position in shares of Evelo Biosciences in the 4th quarter valued at $86,000. Hedge funds and other institutional investors own 92.20% of the company’s stock.

Evelo Biosciences Company Profile (Get Rating)

Evelo Biosciences, Inc, a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19.

Further Reading

Get a free copy of the Zacks research report on Evelo Biosciences (EVLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evelo Biosciences (NASDAQ:EVLO)

Want More Great Investing Ideas?

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.